Compare Annaly Capital Management, Inc. (NLY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Zoetis Inc — how do they compare? Annaly Capital Management, Inc. trades at $18.3 (market cap $13.77B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 2.2× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (16.42%). Which is the better fit depends on your goals — on Pluang, investors hold Annaly Capital Management, Inc. for 91 Days and Zoetis Inc for 70 Days on average.
| NLY | ZTS | |
|---|---|---|
Market Cap | $13.77B | $30.20B |
Volume | 21,283,879 | 6,175,327 |
Sector | Real Estate | Health |
52-Week High | $24.40 | $147.53 |
52-Week Low | $17.93 | $69.09 |
Typical Hold Time | 91 Days | 70 Days |
Enterprise Value | $135.80B | $37.76B |
Dividend Yield | 16.42% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLY trades at $18.27, up 1.9% with strong recent earnings beats (Q2 2026 EPS of $0.79 vs. $0.751 expected). The stock shows bearish technical signals but attractive valuation with P/E of 4.41 and P/B of 0.91. Recent news highlights the 14.7% dividend yield and portfolio expansion to $107 billion in 2026. Cash flow trends show improving net cash flow from $550M in 2025 to projected $853M in 2026.
NLY presents a high-yield opportunity with sustainable dividends supported by strong portfolio growth, though technical indicators signal caution. The stock trades at a discount to analyst consensus target of $22.00 (57% buy ratings). Key risks include interest rate sensitivity and mortgage spread volatility, but fundamental strength supports the current yield.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
